




RealRate

PHARMACEUTICAL 2015

Ernexa Therapeutics Inc
Rank 164 of 274



The relative strengths and weaknesses of Ernexa Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Ernexa Therapeutics Inc compared to the market average is the variable Revenues, increasing the Economic Capital Ratio by 97% points. The greatest weakness of Ernexa Therapeutics Inc is the variable Stockholders Equity, reducing the Economic Capital Ratio by 122% points.

The company's Economic Capital Ratio, given in the ranking table, is 239%, being 15% points below the market average of 254%.

Input Variable	Value in 1000 USD	Output Variable	Value in 1000 USD
Assets, Current	14,872	Assets	22,268
Cost of Goods Sold	0	Liabilities	11,344
Intangible Assets	1,213	Expenses	30,872
Liabilities, Current	7,093	Revenues	26,046
Liabilities, Non-Current	7.0	Stockholders Equity	10,924
Other Assets	2,783	Net Income	-5,030
Other Compr. Net Income	0	Comprehensive Net Income	-5,030
Other Expenses	12,505	BaseVar	45,367
Other Liabilities	4,244	ECR before LimitedLiability	112%
Other Net Income	-204	Economic Capital Ratio	239%
Other Revenues	26,046		
Property and Equipment	3,400		
Research and Development	0		
Selling, General and Administrative Expense	18,367		